Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.
Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.
Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.
The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.
Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.
Confo Therapeutics, de jonge Belgische ontwikkelaar van innovatieve geneesmiddelen gericht op G-proteïne gekoppelde receptoren (GPCRs), kondigt een onderzoekssamenwerking aan met het Deens farmabedrijf H. Lundbeck A/S, een wereldwijde speler gespecialiseerd in neurologische en psychiatrische aandoeningen. De Confo® technologie zal ingezet worden om nieuwe therapeutische moleculen op 2 GPCR targets te identificeren.
Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce that it has signed a binding Head of Terms agreement with Libbs, the Women’s Health leader in Brazil, for an exclusive license to commercialize Estelle®, Mithra’s novel combined oral contraceptive (COC) product candidate, in Brazil.
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the initiation of a Phase II proof-of-concept clinical trial of ARGX-113 in pemphigus vulgaris (PV) patients.
Camel-IDS, a privately held clinical stage radionuclide therapy company in oncology, today announces the appointment of Ruth Devenyns as Chief Executive Officer and director.
Promethera Biosciences SA, a global innovator in cell-based medicines, today announced that the Company will give presentations at several upcoming scientific and partnering conferences in Asia, Europe and the US.
VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.
imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.
Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes.
UNDER CONSTRUCTION: here you will be able to consult the archive of our quarterly e-letter.